Aerie Pharmaceuticals, Inc. (AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today potentially breakthrough findings from new preclinical research. The research found that RhopressaTM suppressed the activity of profibrotic proteins – TGF-beta 2 and CTGF – on human trabecular meshwork cells in an in vitro model. In addition to RhopressaTM’s potential anti-fibrotic activity, another recent Aerie preclinical study indicates that RhopressaTM may increase the perfusion of the trabecular meshwork with aqueous humor.
Read the entire article here